Overview: Leukemia Acute T B Myeloid Panel
Introduction: The Leukemia Acute T B Myeloid Panel is a diagnostic tool designed to diagnose acute leukemia using whole blood or bone marrow samples. In India, acute leukemias (ALL ~70-80 percent pediatric, AML adult predominant) cause ~30,000â€"40,000 new cases yearly, with high mortality in rural/low-SES due to delayed induction chemotherapy. High burden from under-testing leading to misdiagnosis as infection/anemia, inappropriate antibiotics, or late referral. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 47 T/B/myeloid markers (CD3, CD4, CD7, CD19, CD13, CD33, MPO, TdT, CD34, etc.) over 1-2 days with high accuracy, valuable for lineage determination (B-ALL, T-ALL, AML) and risk stratification. This diagnostic falls under leukemia screening and targets patients with blasts, cytopenias, or organomegaly, addressing accurate detection to guide ALL/AML protocols or targeted therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise lineage classification and improving survival. Its blood/bone marrow-based approach ensures reliable multi-lineage analysis.
Other Names: Leuk Acute Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.
Historical Milestone: Acute leukemia flow panel standard; in India, used in pediatric/adult oncology.
Purpose: The test assesses 47 parameters including T/B/myeloid markers to guide acute leukemia diagnosis, assign lineage, inform chemotherapy.
Test Parameters: 1â€"47. T/B/Myeloid Markers (CD3, CD4, CD7, CD19, CD13, CD33, etc.).
Pretest Condition: No fasting required; patients should have blasts or cytopenias.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow/PCR).
Medical History: Patients should provide details on fever, bleeding, lymphadenopathy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed acute leukemia including mortality, benefits of profiling, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Lineage-specific markers confirm ALL/AML subtype, necessitating specialist input.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: Cytogenetics, molecular (FLT3, NPM1) for confirmation.
Test Limitations: Requires viable blasts; comprehensive approach required.
References: Indian Journal of Hematology 2024, Leukemia Studies India 2023.
